SEARCH

SEARCH BY CITATION

References

  • Aalto Y, Eriksson L, Seregard S, Larsson O & Knuutila S (2001): Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 42: 313317.
  • Camelo S, Kezic J, Shanley A, Rigby P & McMenamin PG (2006): Antigen from the anterior chamber of the eye travels in a soluble form to secondary lymphoid organs via lymphatic and vascular routes. Invest Ophthalmol Vis Sci 47: 10391046.
  • Clarijs R, Schalkwijk L, Ruiter DJ & de Waal RM (2003): EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 44: 18011806.
  • Diener-West M, Earle JD, Fine SL et al. (2001): The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 119: 969982.
  • Djano J, Griffin B, van Bruggen I & McMenamin PG (1999): Environmental scanning electron microscopic study of macrophages associated with the tunica vasculosa lentis in the developing rat eye. Br J Ophthalmol 83: 13841385.
  • Fuchs A, Kivelä T, Tarkkanen A & Laatikainen L (1988): Histopathology of enucleated intraocular melanomas irradiated with cobalt and ruthenium plaques. Acta Ophthalmol (Copenh) 66: 255266.
  • Fuchs U, Kivelä T, Summanen P, Immonen I & Tarkkanen A (1992): An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 141: 169181.
  • Gunduz K, Shields CL, Shields JA, Cater J & Brady L (2000): Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol 130: 97102.
  • Heikkonen J, Summanen P, Immonen I, Tommila P, Toivola H, Forss M & Tarkkanen A (1992): Radiotherapy of malignant melanoma of the uvea with I-125 seeds. Acta Ophthalmol (Copenh) 70: 780785.
  • Hogan MJ, Alvarado JA & Weddell JE (1971): Histology of the human eye. An atlas and textbook. Philadelphia, PA: W.B. Saunders.
  • Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A & Littman DR (2000): Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 20: 41064114.
  • Kivelä T (1995): Immunohistochemical staining followed by bleaching of melanin: a practical method for ophthalmic pathology. Br J Biomed Sci 52: 325326.
  • Liszauer AD, Brownstein S, Corriveau C & Deschenes J (1990): A clinicopathological study of seven globes enucleated after primary radiation therapy for malignant melanoma of the choroid or ciliary body. Can J Ophthalmol 25: 340344.
  • Lommatzsch PK, Werschnik C & Schuster E (2000): Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 238: 129137.
  • Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE & Jager MJ (2008): Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 49: 505510.
  • Mäkitie T, Tarkkanen A & Kivelä T (1998): Comparative immunohistochemical oestrogen receptor analysis in primary and metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol 236: 415419.
  • Mäkitie T, Summanen P, Tarkkanen A & Kivelä T (1999a): Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 40: 24712480.
  • Mäkitie T, Summanen P, Tarkkanen A & Kivelä T (1999b): Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 91: 359367.
  • Mäkitie T, Summanen P, Tarkkanen A & Kivelä T (2001): Tumor-infiltrating macrophages (CD68+ cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 42: 14141421.
  • McMenamin PG, Djano J, Wealthall R & Griffin BJ (2002): Characterization of the macrophages associated with the tunica vasculosa lentis of the rat eye. Invest Ophthalmol Vis Sci 43: 20762082.
  • Messmer E, Bornfeld N, Foerster M, Schilling H & Wessing A (1992): Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefes Arch Clin Exp Ophthalmol 230: 391396.
  • Polak ME, Borthwick NJ, Johnson P, Hungerford JL, Higgins B, Di PS, Jager MJ & Cree IA (2007): Presence and phenotype of dendritic cells in uveal melanoma. Br J Ophthalmol 91: 971976.
  • Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH & Becher R (1996): Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347: 12221225.
  • Schilling H, Sehu KW & Lee WR (1997): A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 38: 20812092.
  • Schlesselman JJ (1982): Case-control studies: design, conduct, analysis. New York: Oxford University Press.
  • Schmollinger JC & Dranoff G (2004): Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy. Apoptosis 9: 309313.
  • Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA & Cursiefen C (2008): The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci 49: 52225229.
  • Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B & Brady LW (2000): Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol 118: 12191228.
  • Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM & Rees RC (1997): Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19: 2228.
  • Streilein JW, Wilbanks GA, Taylor A & Cousins S (1992): Eye-derived cytokines and the immunosuppressive intraocular microenvironment – A review. Curr Eye Res 11: 4147.
  • The Collaborative Ocular Melanoma Study Group (1998): Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 125: 745766.
  • Toivonen P & Kivelä T (2006): Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology 113: 865873.
  • Toivonen P, Mäkitie T, Kujala E & Kivelä T (2003): Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res 27: 237245.
  • de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL & Jager MJ (1996): HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol 234: 3442.
  • White VA, Chambers JD, Courtright PD, Chang WY & Horsman DE (1998): Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83: 354359.
  • Wilbanks GA & Streilein JW (1991): Studies on the induction of anterior chamber-associated immune deviation (ACAID) .1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral-blood. J Immunol 146: 26102617.